|
1
|
Wagner MJ, Ravi V, Schaub SK, Kim EY,
Sharib J, Mogal H, Park M, Tsai M, Duarte-Bateman D, Tufaro A, et
al: Incidence and presenting characteristics of angiosarcoma in the
US, 2001–2020. JAMA Netw Open. 7:e2462352024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Young RJ, Brown NJ, Reed MW, Hughes D and
Woll PJ: Angiosarcoma. Lancet Oncol. 11:983–991. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Deb PQ, Weiss RE and Heller DS:
Angiosarcoma of the uterus: A systematic review. Int J Gynecol
Pathol. 41:496–502. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kruse AJ, Sep S, Slangen BF, Vandevijver
NM, Van Gorp T, Kruitwagen RF and de Vijver KK: Angiosarcomas of
primary gynecologic origin: A clinicopathologic review and
quantitative analysis of survival. Int J Gynecol Cancer. 24:4–12.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Penel N, Italiano A, Ray-Coquard I,
Chaigneau L, Delcambre C, Robin YM, Bui B, Bertucci F, Isambert N,
Cupissol D, et al: Metastatic angiosarcomas: Doxorubicin-based
regimens, weekly paclitaxel and metastasectomy significantly
improve the outcome. Ann Oncol. 23:517–523. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Konishi Y, Sato H, Fujimoto T, Tanaka H,
Takahashi O and Tanaka T: A case of primary uterine angiosarcoma:
Magnetic resonance imaging and computed tomography findings. Int J
Gynecol Cancer. 17:280–284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Di Donato V, Kontopantelis E, Cuccu I,
Sgamba L, Golia D'Augè T, Pernazza A, Rocca CD, Manganaro L,
Catalano C, Perniola G, et al: Magnetic resonance imaging-radiomics
in endometrial cancer: A systematic review and meta-analysis. Int J
Gynecol Cancer. 33:1070–1076. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schammel DP and Tavassoli FA: Uterine
angiosarcomas: A morphologic and immunohistochemical study of four
cases. Am J Surg Pathol. 22:246–250. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gronchi A, Miah AB, Dei Tos AP, Abecassis
N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, et
al: Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 32:1348–1365. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Conforti F, Gronchi A, Penel N, Jones RL,
Broto JM, Sala I, Bagnardi V, Napolitano A, Pala L, Pennacchioli E,
et al: Chemotherapy in patients with localized angiosarcoma of any
site: A retrospective European study. Eur J Cancer. 171:183–192.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Italiano A, Cioffi A, Penel N, Levra MG,
Delcambre C, Kalbacher E, Chevreau C, Bertucci F, Isambert N, Blay
JY, et al: Comparison of doxorubicin and weekly paclitaxel efficacy
in metastatic angiosarcomas. Cancer. 118:3330–3336. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Young RJ, Natukunda A, Litière S, Woll PJ,
Wardelmann E and van der Graaf WT: First-line anthracycline-based
chemotherapy for angiosarcoma and other soft tissue sarcoma
subtypes: Pooled analysis of eleven EORTC soft tissue and bone
sarcoma group trials. Eur J Cancer. 50:3178–3186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schlemmer M, Reichardt P, Verweij J,
Hartmann JT, Judson I, Thyss A, Hogendoorn PC, Marreaud S, Van
Glabbeke M and Blay JY: Paclitaxel in patients with advanced
angiosarcomas of soft tissue: A retrospective study of the EORTC
soft tissue and bone sarcoma group. Eur J Cancer. 44:2433–2436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Penel N, Bui BN, Bay JO, Cupissol D,
Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S,
Jimenez M, et al: Phase II trial of weekly paclitaxel for
unresectable angiosarcoma: The ANGIOTAX study. J Clin Oncol.
26:5269–5274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stacchiotti S, Palassini E, Sanfilippo R,
Vincenzi B, Arena MG, Bochicchio AM, De Rosa P, Nuzzo A, Turano S,
Morosi C, et al: Gemcitabine in advanced angiosarcoma: A
retrospective case series analysis from the Italian rare cancer
network. Ann Oncol. 23:501–508. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Roma AA, Allende D, Fadare O, Forscher C
and Rutgers JK: On uterine angiosarcomas: 2 additional cases. Int J
Gynecol Pathol. 36:369–371. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Strickland SV, Kilgore MR, Simons EJ and
Rendi MH: Epithelioid angiosarcoma arising in a uterine leiomyoma
with associated elevated CA-125: A case report. Gynecol Oncol Rep.
21:1–4. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang M, Wu S, Tong A, Cui X and Ma X: The
prognostic value of pretreatment inflammatory biomarkers in primary
angiosarcoma. Cancer Manag Res. 11:7981–7989. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wagner MJ, Othus M, Patel SP, Ryan C,
Sangal A, Powers B, Budd GT, Victor AI, Hsueh CT, Chugh R, et al:
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab
and nivolumab in metastatic or unresectable angiosarcoma: A
substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors
(DART). J Immunother Cancer. 9:e0029902021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grilley-Olson JE, Allred JB, Schuetze S,
Davis EJ, Wagner MJ, Poklepovic AS, Waechter B and Schwartz GK: A
multicenter phase II study of cabozantinib plus nivolumab for
patients with advanced angiosarcoma previously treated with a
taxane (Alliance A091902). J Clin Oncol. 41:115032023. View Article : Google Scholar
|
